Fulvestrant vs Anastrozole for Breast Cancer (FALCON Trial)

"Eligible participants for this trial must have a diagnosis of breast cancer and be between 18-130 years old. The study is looking to enroll 462 individuals."

"This study has already completed recruitment and is no longer seeking participants. The trial was initially posted on October 17th, 2012 and was last updated on October 31st, 2022. However, there are still 2357 trials actively searching for patients with breast cancer and 189 studies for faslodex 500mg still looking for participants."

"According to the eligibility requirements, patients aged 18 to 130 can apply to participate in this trial. There are currently 68 studies underway for patients under 18 and 2456 for seniors."

"There is some data supporting faslodex 500mg's efficacy and multiple rounds of data supporting its safety, so it received a score of 3."

"The brca1 gene is most often treated with faslodex 500mg. However, faslodex 500mg is also effective against other conditions, like breast cancer, malignant neoplasms, and pik3ca gene mutation."

"Data from clinicaltrials.gov suggests that this study is no longer recruiting patients. This specific trial was first posted on October 17th, 2012 and was last edited on October 31st, 2022. Although this particular study is not enrolling patients, there are 2546 other clinical trials with open recruitment at this time."

"As of now, 189 clinical trials are underway to research faslodex 500mg with 49 of those trials in Phase 3. Most of the faslodex 500mg research is taking place in Correggio, RE, but there are 11777 total locations running trials for faslodex 500mg."

"To limit the burden of travel on participants, this study is recruiting from 19 sites that are based in or near major cities including Montgomery, Savannah and Saint Louis."